Early human studies. This label summarises the type of data; it is neither a recommendation to use nor a safety rating.
How we read studies and personal accounts ↗Identity
Cannabidivarin is a cannabinoid distinct from CBD; similar names do not establish clinical equivalence.
Terms associated with this entry: cannabidivarin, cannabidivarol.
The placebo group changed too
In the focal-seizure trial involving 162 adults, frequency decreased in both groups, without a significant difference between CBDV and placebo. The comparison did not confirm an added effect.
Another trial, another unconfirmed question
The crossover trial of HIV-associated neuropathic pain analysed 32 patients. CBDV likewise did not significantly reduce pain compared with placebo. The result does not confirm analgesic efficacy in that population.
A negative result is informative too
The most useful profiles retain results that complicate the story. An animal signal may justify a trial without being reproduced in patients. A group can improve for many reasons. Comparison prevents automatically attributing every change to the substance. That discipline protects both readers and the value of research.
What has been studied
The two trials described do not confirm benefit over placebo on their primary outcomes.
Risks and gaps
Diarrhoea, nausea and sleepiness were common in the epilepsy trial; transaminase elevations were also recorded.
Documented forms
| Experimental pharmaceutical formulation | Describes the investigated material, not a recommended treatment or marketing authorisation. |
|---|
A molecule and a product are different things. Read about flowers, resins, oils, creams, capsules and vaping.
Experiences
We have not included a verifiable individual account in this review. We do not fill that gap with commercial stories or invented experiences.
Conclusion
CBDV shows why an encyclopedia should report comparisons, not just expectations. Similarity to CBD may generate interest, but does not transfer its indications or replace CBDV’s own results.
Legal context
Read the Spain note and official sources. Absence from a cited list does not establish that a product is lawful.
Sources
- A Phase 2 Randomized Controlled Trial of Cannabidivarin in Focal Seizures, 2021 · Human trial
- Cannabidivarin for HIV-Associated Neuropathic Pain · Human trial
Source review: 2026-11-02. No external clinical review. Corrections: info@milnubes.com.